We're working towards transforming care for patients with atrial fibrillation.

Atrial fibrillation is a common cardiac arrhythmia that can lead to blood clots, stroke, heart failure and other cardiovascular problems.¹

Despite advances in antithrombotic treatment, the use of anticoagulation therapy is limited in individuals with a high risk of bleeding, leaving many atrial fibrillation patients at risk for stroke.³



According to 2019 global data, an estimated

55.4 million people are affected by atrial fibrillation.

Individuals with atrial fibrillation have a

4- to 5-fold higher risk

of stroke compared to the general population.

Johnson & Johnson